Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $20,646 - $36,400
3,077 Added 6.46%
50,686 $340,000
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $240,014 - $296,103
12,835 Added 36.91%
47,609 $958,000
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $16,688 - $25,161
921 Added 2.72%
34,774 $788,000
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $93,950 - $141,312
5,533 Added 19.54%
33,853 $635,000
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $6,935 - $10,255
477 Added 1.71%
28,320 $511,000
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $32,444 - $57,724
1,603 Added 6.11%
27,843 $577,000
Q3 2021

Nov 15, 2021

BUY
$26.01 - $38.22 $10,039 - $14,752
386 Added 1.49%
26,240 $839,000
Q2 2021

Aug 16, 2021

SELL
$29.97 - $37.17 $217,971 - $270,337
-7,273 Reduced 21.95%
25,854 $796,000
Q4 2020

Mar 01, 2021

SELL
$35.35 - $50.67 $20 Million - $28.7 Million
-566,171 Reduced 94.47%
33,127 $1.2 Million
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $14.6 Million - $19.4 Million
-406,361 Reduced 40.41%
599,298 $22.1 Million
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $12.8 Million - $19.2 Million
283,243 Added 39.21%
1,005,659 $45.3 Million
Q1 2020

May 15, 2020

BUY
$40.01 - $73.97 $5.87 Million - $10.8 Million
146,590 Added 25.46%
722,416 $34.3 Million
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $12.8 Million - $25.7 Million
344,276 Added 148.68%
575,826 $41.3 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $620,707 - $1.21 Million
15,770 Added 7.31%
231,550 $9.11 Million
Q2 2019

Aug 15, 2019

BUY
$52.76 - $82.19 $10.6 Million - $16.5 Million
200,974 Added 1357.38%
215,780 $0
Q1 2019

May 14, 2019

BUY
$27.39 - $68.41 $148,234 - $370,234
5,412 Added 57.61%
14,806 $0
Q4 2018

Feb 13, 2019

BUY
$22.8 - $33.93 $68,263 - $101,586
2,994 Added 46.78%
9,394 $270,000
Q3 2018

Nov 14, 2018

BUY
$29.75 - $43.08 $190,400 - $275,712
6,400 New
6,400 $0

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.